MCM
IMMX icon

MAI Capital Management’s Immix Biopharma IMMX Stock Holding History

MAI Capital Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,000
Closed -$4.18K – 4413
2025
Q3 		$4.18K Buy
+2,000
New +$4.8K ﹤0.01% 3084

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

MAI Capital Management's IMMX Position: Q4 2025 in Review

MAI Capital Management sold out of Immix Biopharma (IMMX) in Q4 2025, closing a stake of 2,000 shares — an estimated $4.18K sold.

MAI Capital Management first reported a position in IMMX in Q3 2025 and held it in 1 quarter. The position peaked at $4.18K in Q3 2025. 67 funds tracked by Wall St. Rank hold IMMX as of Q4 2025.

  • MAI Capital Management reported no remaining Immix Biopharma position as of Q4 2025 after selling out during the quarter.
  • MAI Capital Management sold 2,000 Immix Biopharma shares in Q4 2025, an estimated $4.18K.
  • MAI Capital Management first reported a position in Immix Biopharma in Q3 2025 and held it in 1 quarter.
  • MAI Capital Management's Immix Biopharma position peaked at $4.18K in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Immix Biopharma as of Q4 2025.

Based on MAI Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.